Want to see IBIO full AI Analyst Report?
Top Page
Ibio
(NASDAQ:IBIO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.70
▼(-52.72% Downside)
Action:Reiterated
Date:10/21/26
IBIO scores low primarily due to very weak financial performance (minimal and declining revenue, large losses, and significant ongoing cash burn) and a clearly bearish technical setup (price below all key moving averages with negative MACD). Corporate events provide some support via positive pipeline/preclinical updates and financing flexibility, but these positives are not enough to offset the current fundamentals and trend.
Positive Factors
Low Leverage
The low debt burden reduces near-term balance-sheet stress and leaves more flexibility to fund research, manage volatility, or pursue strategic priorities. This is an important structural support for a development-stage biotech, although it does not offset the company’s continuing operating losses and cash consumption.
Negative Factors
Minimal Declining Revenue
Extremely small and declining revenue indicates that iBio has not yet established meaningful commercial traction or a dependable operating revenue base. This leaves the company reliant on future product development success rather than current business activity to support growth and build sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
The low debt burden reduces near-term balance-sheet stress and leaves more flexibility to fund research, manage volatility, or pursue strategic priorities. This is an important structural support for a development-stage biotech, although it does not offset the company’s continuing operating losses and cash consumption.
Read all positive factors
Ibio (IBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.68M
Dividend YieldN/A
Average Volume (3M)810.37K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-75.00%
EPS Growth74.04%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding60,853,560
10 Day Avg. Volume929,510
30 Day Avg. Volume810,368
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.12
Price to Sales (P/S)1821.05
P/FCF Ratio-7.65
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue116.31
Enterprise Value/Gross Profit116.31
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$6.00Price Target Upside308.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$25.00K
Ibio Business Overview & Revenue Model
Company Description
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Biopr...
Ibio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 100.00K | 400.00K | 225.00K | 0.00 | 1.88M |
| Gross Profit | 100.00K | 400.00K | 225.00K | 0.00 | -1.91M |
| EBITDA | -31.96M | -17.04M | -14.02M | -27.85M | -25.72M |
| Net Income | -33.04M | -18.38M | -24.91M | -65.01M | -50.39M |
Balance Sheet | |||||
| Total Assets | 99.11M | 23.18M | 28.73M | 41.21M | 99.41M |
| Cash, Cash Equivalents and Short-Term Investments | 88.04M | 8.58M | 14.21M | 7.33M | 33.52M |
| Total Debt | 2.20M | 3.51M | 4.46M | 17.07M | 25.77M |
| Total Liabilities | 13.40M | 8.30M | 7.41M | 25.83M | 35.92M |
| Stockholders Equity | 85.71M | 14.88M | 21.32M | 15.38M | 63.48M |
Cash Flow | |||||
| Free Cash Flow | -23.80M | -15.32M | -18.76M | -36.17M | -45.13M |
| Operating Cash Flow | -23.22M | -15.30M | -18.55M | -30.44M | -37.80M |
| Investing Cash Flow | -32.00M | 742.00K | 906.00K | 7.01M | -5.13M |
| Financing Cash Flow | 103.05M | 8.93M | 24.49M | 2.30M | -5.80M |
Ibio Technical Analysis
Negative
1.47
Price Trends
1.16
Negative
1.36
Negative
1.74
Negative
Market Momentum
-0.12
Positive
24.54
Positive
24.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Negative. The current price of 1.47 is above the 20-day moving average (MA) of 0.93, above the 50-day MA of 1.16, and below the 200-day MA of 1.74, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 24.54 is Positive, neither overbought nor oversold. The STOCH value of 24.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBIO.
Ibio Risk Analysis
Ibio disclosed 62 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ibio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $5.41M | -1.35 | -109.26% | ― | -100.00% | 49.19% | |
44 Neutral | $43.68M | -2.21 | -47.92% | ― | -75.00% | 74.04% | |
42 Neutral | $7.46M | -1.01 | -70.81% | ― | ― | 56.99% | |
42 Neutral | $109.82M | -0.08 | 250.02% | ― | ― | -2012.66% | |
41 Neutral | $6.33M | -0.16 | -536.78% | ― | ― | 22.10% |
* Healthcare Sector Average
IBIO
Ibio
0.72
-0.56
-43.98%
NERV
Minerva Neurosciences
2.30
-2.23
-49.23%
PULM
Pulmatrix
1.48
-3.45
-69.98%
CMMB
Chemomab Therapeutics
1.03
-2.02
-66.23%
ASBP
Aspire Biopharma Holdings
8.80
-408.08
-97.89%
FBLG
FibroBiologics, Inc.
0.95
-7.71
-89.02%
Ibio Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
iBio Shareholders Approve Governance and Capital Structure Changes
Positive
Oct 19, 2026
iBio, Inc. is a biotechnology company focused on developing therapeutics and vaccines using its proprietary technology platforms. The company operates in the life sciences industry and relies on equity-based incentive plans and access to capital m...
Business Operations and StrategyProduct-Related Announcements
iBio Highlights IBIO-610 Obesity Antibody Preclinical Results
Positive
Oct 13, 2026
On Oct. 13, 2026, iBio reported preclinical body-composition data from an eight-week obese non-human primate study of IBIO-610, a potentially first-in-class Activin E antibody, tested alone and with the GLP-1 agonist semaglutide used for obesity. ...
Business Operations and StrategyProduct-Related Announcements
iBio Highlights Breakthrough Antibody Strategy for Obesity
Positive
Sep 14, 2026
In September 2026, iBio updated its corporate presentation to highlight a strategic focus on “breakthrough antibodies” for obesity and cardiometabolic diseases, positioning itself as a next-generation player beyond first-wave GLP-1 inc...
Business Operations and StrategyExecutive/Board Changes
iBio Appoints Molly Carr as Chief Medical Officer
Positive
Aug 4, 2026
On July 31, 2026, iBio appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer, and publicly announced the move on August 4, 2026 as part of efforts to bolster its clinical leadership for obesity and cardiometabolic programs. Carr, a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.